Prevalence of and Risk Factors for Prediabetes in Patients Infected With HIV

Syed Arafath, Tavajay Campbell, Jameela Yusuff, Roopali Sharma, Syed Arafath, Tavajay Campbell, Jameela Yusuff, Roopali Sharma

Abstract

Background: The use of highly active antiretroviral therapy (HAART) has resulted in a dramatic decrease in morbidity and mortality in HIV-infected patients. Components of HAART (e.g., protease inhibitors and nucleoside reverse transcriptase inhibitors), as well as HIV infection itself, can have significant effects on developing new-onset diabetes. The goals of this study were to determine the prevalence of prediabetes and to assess risk factors associated with prediabetes in a cohort of HIV-infected patients.

Methods: This is a retrospective, cross-sectional study of 249 HIV-infected patients in an outpatient multidisciplinary HIV clinic in a university hospital. Patients with prediabetes were identified and compared with patients without prediabetes. The association between the prevalence of prediabetes and risk factors was analyzed.

Results: Among 249 HIV-infected patients, the mean age was 46.3 years, and 54% were male. Prevalence of prediabetes was approximately 30%, and BMI ≥30 kg/m2 was found to be a significant risk factor for developing prediabetes.

Conclusion: A high prevalence of prediabetes was observed in this cohort of HIV-infected patients. Interventions targeting HIV-infected patients with increased risk of prediabetes, especially individuals with a high BMI, is needed.

References

    1. Palella FJ, Delaney KM, Moorman AC, et al. . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853–860
    1. DeWit S, Sabin CA, Weber R, et al. . Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008;31:1224–1229
    1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Health, United States, 2013: With Special Feature on Prescription Drugs. . 2014. Accessed 20 December 2016
    1. Mulligan K, Grunfeld C, Tai VW, et al. . Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35–43
    1. Kalra S, Kalra B, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011;3:2.
    1. Fleishman A, Johnsen S, Systrom DM, et al. . Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007;292:E1666–E1673
    1. Nix L, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014;11:271–278
    1. Smith GH. HIV opening statement of Senator Gordon H. Smith, Chairman. In Over Fifty: Exploring the New Threat. Transcript of a U.S. Senate Special Committee on Aging hearing on 12 May 2005. Washington, D.C, U.S. Government Printing Office, 2005
    1. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Ann Rev Med 2011;62:141–155
    1. Kuller LH, Tracy R, Belloso W, et al. . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;21.5:e203
    1. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010;33:2244–2249
    1. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2 in Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39 (Suppl. 1):S13–S22
    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services, 2014
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Srivanich N, Ngarmukos C, Sungkanuparph S. Prevalence of and risk factors for pre-diabetes in HIV-1 infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care 2010;9:358–361
    1. Calza L, Masetti G, Piergentilli B, et al. . Prevalence of diabetes mellitus, hyperinsulinaemia, and metabolic syndrome among 775 adult patients with HIV-1 infection. Int J STD AIDS 2011;22:43–45
    1. Khaodhiar L, Cummings S, Apovian CM. Treating diabetes and prediabetes by focusing on obesity management. Curr Diab Rep 2009;9:348–354
    1. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 2009;32:S373–S377
    1. Gebreyesus HA. Prevalence of prediabetes in HIV-1 infected adults receiving antiretroviral therapy in Addis Ababa, Ethiopia. Int J Pharm Sci Res 2015;6:440–443
    1. Brown TT, Cole SR, Kingsley LA, et al. . Antiretroviral therapy and the prevalence and incidence of diabetes in a multicenter AIDS cohort study. Arch Intern Med 2005;165:1179–1184
    1. Woerle HJ, Marivz PR, Meyer C, et al. . Mechanisms for the deterioration in glucose tolerance associated with protease inhibitor regimen. Diabetes 2003;52:918–925
    1. Bouchard PH, Sai P, Reach G, Caubarrere I, Ganeval D, Assa R. Diabetes following pentamidine-induced hypoglycemia in humans. Diabetes 1982;31:40–45
    1. Rhee JY, Bahtila TD, Palmer D, et al. . Prediabetes and diabetes among HIV-infected adults in Cameroon. Diabetes Metab Res Rev 2016;32:544–549
    1. Martinez E, Garcia-Viejo MA, Blanco JL, et al. . Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266–1273

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner